Picture of Zevia PBC logo

ZVIA — Zevia PBC News Story

0.000.00%
us flag iconLast trade - 00:00
Consumer DefensivesSpeculativeSmall CapNeutral

Brief: Zevia Q2 Adjusted EBITDA USD 200 Thousand Vs. IBES Estimate USD -2.45 Million

Overview

Zevia Q2 net sales rise 10.1% to $44.5 mln, beating expectations

Adjusted EBITDA turns positive, beating analyst estimates, per LSEG data

Net loss narrows to $0.7 mln

Outlook

Zevia expects Q3 2025 net sales of $38 mln to $40 mln

Company expects 2025 adjusted EBITDA to reflect marketing reinvestment

Result Drivers

VOLUME GROWTH - Net sales increase driven by 14.3% volume growth, largely from expanded distribution at Walmart and drug channel

GROSS PROFIT MARGIN - Improvement in gross profit margin due to lower product costs and better inventory management

SELLING EXPENSES - Reduced selling expenses due to savings in freight and warehousing costs from Productivity Initiative

Key Details

MetricBeat/MissActualConsensus Estimate
Q2 SalesBeat$44.52 mln$41.70 mln (5 Analysts)
Q2 EPS-$0.01
Q2 Adjusted EBITDABeat$200,000-$2.45 mln (4 Analysts)
Q2 Gross Profit$21.69 mln
Q2 Income from Operations-$1.02 mln
Q2 Operating Expenses$22.71 mln
Q2 Pretax Profit-$634,000
Analyst Coverage The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell" The average consensus recommendation for the non-alcoholic beverages peer group is "buy" Wall Street's median 12-month price target for Zevia PBC is $5.00, about 34.4% above its August 5 closing price of $3.28 Press Release: ID:nBw28pNqda (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Zevia PBC

See all news